Profile data is unavailable for this security.
About the company
Embecta Corp. is a global medical device company. The Company is focused on providing solutions to people living with diabetes. The Company has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The Company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through a variety of channels, including retail, hospitals, pharmacies and other institutional channels.
- Revenue in USD (TTM)1.13bn
- Net income in USD70.20m
- Incorporated2021
- Employees2.20k
- LocationEmbecta Corp300 Kimball Drive, Suite 300PARSIPPANY NJ 07054United StatesUSA
- Phone+1 (862) 401-0000
- Fax+1 (302) 655-5049
- Websitehttps://www.embecta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacific Biosciences of California Inc | 200.43m | -296.90m | 487.52m | 796.00 | -- | 0.751 | -- | 2.43 | -1.14 | -1.14 | 0.7695 | 2.38 | 0.1124 | 2.21 | 6.69 | 251,797.70 | -16.65 | -16.19 | -18.40 | -17.81 | 28.81 | 37.35 | -148.13 | -136.21 | 8.36 | -21.84 | 0.5791 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Orthofix Medical Inc | 760.05m | -126.48m | 515.28m | 1.63k | -- | 0.9006 | -- | 0.678 | -3.40 | -3.40 | 20.42 | 15.24 | 0.8338 | 1.16 | 6.36 | 465,143.80 | -13.87 | -8.88 | -16.48 | -10.96 | 66.20 | 72.37 | -16.64 | -9.28 | 1.19 | -8.38 | 0.194 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Bioventus Inc | 522.74m | -21.65m | 532.62m | 995.00 | -- | 3.10 | 20.87 | 1.02 | -0.3438 | -0.3438 | 8.30 | 2.16 | 0.6217 | 1.95 | 4.28 | 538,910.30 | -3.23 | -5.52 | -4.47 | -7.27 | 65.55 | 68.25 | -5.20 | -10.94 | 0.9745 | 1.03 | 0.6428 | -- | 0.0445 | 9.93 | 6.91 | -- | 23.51 | -- |
| Iradimed Corp | 67.69m | 17.92m | 537.85m | 148.00 | 30.18 | 7.07 | 28.71 | 7.95 | 1.41 | 1.41 | 5.31 | 6.01 | 0.8273 | 1.67 | 5.51 | 457,333.40 | 21.91 | 13.16 | 24.02 | 14.58 | 76.57 | 76.55 | 26.48 | 21.46 | 7.77 | -- | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| SI-Bone Inc | 144.05m | -43.12m | 578.93m | 344.00 | -- | 3.49 | -- | 4.02 | -1.08 | -1.08 | 3.61 | 4.03 | 0.7728 | 1.62 | 6.44 | 418,735.50 | -23.13 | -27.88 | -25.72 | -30.94 | 78.10 | 85.03 | -29.93 | -51.09 | 8.75 | -- | 0.1791 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
| Surmodics Inc | 142.96m | 13.50m | 599.78m | 376.00 | 43.83 | 4.84 | 26.97 | 4.20 | 0.9597 | 0.9597 | 10.14 | 8.69 | 0.8194 | 2.05 | 6.66 | 380,220.80 | 7.74 | -1.85 | 8.69 | -2.18 | 79.11 | 82.93 | 9.44 | -2.98 | 3.59 | 9.66 | 0.1921 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Fulgent Genetics Inc | 287.53m | -165.95m | 617.94m | 1.18k | -- | 0.5463 | -- | 2.15 | -5.57 | -5.57 | 9.64 | 37.80 | 0.2206 | -- | 6.01 | 242,846.30 | -13.29 | 16.70 | -14.16 | 18.37 | 37.47 | 67.89 | -60.25 | 29.06 | -- | -- | 0.0014 | 0.00 | -53.27 | 68.41 | -217.03 | -- | 57.08 | -- |
| Varex Imaging Corp | 855.80m | 41.90m | 631.91m | 2.30k | 25.58 | 1.10 | 8.21 | 0.7384 | 0.604 | 0.604 | 16.18 | 14.10 | 0.7008 | 1.94 | 5.50 | 356,583.30 | 3.47 | 0.9913 | 4.03 | 1.18 | 32.39 | 31.70 | 4.95 | 1.36 | 2.37 | 2.57 | 0.4292 | -- | 3.96 | 2.93 | 59.08 | 18.88 | 0.2924 | -- |
| Pulse Biosciences Inc | 0.00 | -42.55m | 637.85m | 56.00 | -- | 17.58 | -- | -- | -0.8152 | -0.8152 | 0.00 | 0.6571 | 0.00 | -- | -- | 0.00 | -71.28 | -93.21 | -79.29 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| Paragon 28 Inc | 225.44m | -54.02m | 637.90m | 430.00 | -- | 3.88 | -- | 2.83 | -0.6536 | -0.6536 | 2.73 | 1.98 | 0.6956 | 0.5405 | 5.82 | 524,267.40 | -16.67 | -- | -20.52 | -- | 79.21 | -- | -23.96 | -- | 1.78 | -6.45 | 0.4018 | -- | 19.30 | -- | 28.94 | -- | -- | -- |
| Embecta Corp | 1.13bn | 70.20m | 713.38m | 2.20k | 10.17 | -- | 6.74 | 0.6299 | 1.22 | 1.22 | 19.62 | -13.35 | 0.94 | 2.51 | 15.86 | 514,772.70 | 5.83 | -- | 8.06 | -- | 65.57 | -- | 6.20 | -- | 1.79 | 1.51 | 1.89 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
| Cytek Biosciences Inc | 200.79m | -11.51m | 739.07m | 637.00 | -- | 1.88 | -- | 3.68 | -0.0856 | -0.0856 | 1.50 | 2.99 | 0.395 | 1.44 | 4.30 | 297,020.70 | -2.26 | -- | -2.54 | -- | 55.48 | -- | -5.73 | -- | 6.01 | -- | 0.0086 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Orthopediatrics Corp | 161.83m | -21.97m | 752.52m | 247.00 | -- | 2.01 | -- | 4.65 | -0.9647 | -0.9647 | 7.11 | 15.74 | 0.3748 | 0.4247 | 5.13 | 655,178.10 | -5.09 | -5.40 | -5.62 | -5.93 | 74.07 | 75.09 | -13.58 | -15.92 | 1.99 | -- | 0.0271 | -- | 21.62 | 20.91 | -1,767.25 | -- | 28.29 | -- |
| Atrion Corp | 176.67m | 18.72m | 810.02m | 712.00 | 43.28 | 3.35 | 23.65 | 4.59 | 10.63 | 10.63 | 100.32 | 137.46 | 0.6794 | 1.56 | 7.93 | 248,127.80 | 7.20 | 11.96 | 7.63 | 12.62 | 33.77 | 41.99 | 10.60 | 19.05 | 3.06 | -- | 0.00 | 42.42 | -7.73 | 2.12 | -44.55 | -10.74 | 4.98 | 11.27 |
| Silk Road Medical Inc | 185.49m | -53.42m | 857.51m | 474.00 | -- | 5.82 | -- | 4.62 | -1.37 | -1.37 | 4.76 | 3.73 | 0.7247 | 2.08 | 7.87 | 391,322.80 | -20.87 | -29.02 | -22.75 | -32.98 | 73.31 | 72.91 | -28.80 | -46.84 | 9.62 | -- | 0.34 | -- | 27.77 | 38.66 | -1.33 | -- | -7.92 | -- |
| Avanos Medical Inc | 680.10m | -1.60m | 913.95m | 3.77k | -- | 0.747 | 20.87 | 1.34 | -0.0315 | -1.33 | 14.62 | 26.65 | 0.4005 | 1.62 | 5.48 | 180,350.00 | -0.0942 | -0.6527 | -0.1055 | -0.7338 | 56.33 | 54.45 | -0.2353 | -1.60 | 1.47 | 4.85 | 0.1257 | -- | -1.58 | 0.6357 | -146.05 | -- | -18.37 | -- |
Data as of May 31 2024. Currency figures normalised to Embecta Corp's reporting currency: US Dollar USD
62.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.52m | 14.80% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.09m | 12.32% |
| River Road Asset Management LLCas of 31 Mar 2024 | 3.45m | 5.99% |
| Millennium Management LLCas of 31 Mar 2024 | 3.23m | 5.62% |
| American Century Investment Management, Inc.as of 31 Mar 2024 | 3.14m | 5.46% |
| Yacktman Asset Management LPas of 31 Mar 2024 | 2.82m | 4.89% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.52m | 4.38% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.40m | 4.17% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 1.33m | 2.30% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.31m | 2.27% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
